icotec Medical Inc.
$604.4K 1,344 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Endo Pharmaceuticals Inc.
Endo Pharmaceuticals Inc. reported $603,360.60 across General Payments, Research, and Ownership to 4,960 physicians and teaching hospitals across 4,968 transactions.
- $603.4K Above-median payer
- All-tracks total
- 4,968 Top quartile volume
- Transactions
- 4,960 Top quartile reach
- Recipients
- −$1.4M
- General Payments vs PY2023
Endo Pharmaceuticals Inc. reported $603,360.60 across all CMS Open Payments tracks (General + Research + Ownership) to 4,960 physicians and teaching hospitals in Program Year 2024 - ranking #724 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $579,807.93, averaging $121.65 per recipient.
How Endo Pharmaceuticals Inc.'s $603.4K all-tracks total breaks down
Endo Pharmaceuticals Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
47/100
Total payments
F
16/100
Transaction volume
F
46/100
Physician reach
F
48/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer endo-pharmaceuticals-inc Endo Pharmaceuticals Inc.
$603.4K · #724/1,925 · 0.0% industry · PY2024
- TOT $603.4K
- RANK #724
- SHARE 0.0%
- TXN 4,968
- RCP 4,960
- CAT 6
- GEN $579.8K
- ΔGEN −$1.4M
- TOP1 6.2%
- PY 2024
Volume peers
Nearest volume peer: icotec Medical Inc. ($604.4K)
Endo Pharmaceuticals Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Endo Pharmaceuticals Inc.'s CMS-reported General Payments decreased by $1.4M (−70.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ENDO PHARMACEUTICALS INC.PY2023: ENDO PHARMACEUTICALS INC.PY2024: Endo Pharmaceuticals Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,952,230.68
- PY2024
- $579,807.93
What the Data Shows for Endo Pharmaceuticals Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Endo Pharmaceuticals Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 6-category general-payment breakdown below at $198.4K (34.2% of General Payments, 36 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 6 types of general payments, Endo Pharmaceuticals Inc.'s largest category was "Consulting Fee" at $198.4K - 34.2% of General Payments.
Endo Pharmaceuticals Inc. reports 6 general-payment categories - the top three are Consulting Fee (34.2%), Compensation for Services Other Than Consulting (23.8%), and Food and Beverage (21.8%). The remaining 3 categories make up 20.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Endo Pharmaceuticals Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $198.4K | 36 | 34.2% |
| Compensation for Services Other Than Consulting | $138.1K | 61 | 23.8% |
| Food and Beverage | $126.5K | 4,663 | 21.8% |
| Grant | $57.0K | 3 | 9.8% |
| Travel and Lodging | $50.4K | 195 | 8.7% |
| Space Rental or Facility Fees | $9.5K | 2 | 1.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $150,930.70 (26.0%) of $579,807.93 in this company's General Payments records across 3,076 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Endo Pharmaceuticals Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Damon Adamany
$35,847.32 across 41 reported transactions
- 2
Prosper Benhaim
$35,673.32 across 33 reported transactions
- 3
Cleveland Clinic Hospital
$35,000.00 across 1 reported transactions
- 4
Michael Garcia
$22,424.06 across 2 reported transactions
- 5
University of Washington Med Ctr
$21,986.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Endo Pharmaceuticals Inc. ranks #724 of 1,925 by total payments (top 38% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,519 of 1,838 by HHI (bottom 17% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Medtronic, Inc. : $117.7M total payments, HHI 247
- Coloplast Corp : $3.4M total payments, HHI 246
- Elevate Surgical CO : $14.4K total payments, HHI 244
- Alcon Vision LLC : $13.4M total payments, HHI 244
- kaleo, Inc. : $256.5K total payments, HHI 243
- Sandoz Inc. : $239.3K total payments, HHI 239
- Endo Pharmaceuticals Inc. (this company) : $579.8K total payments, HHI 239
- Crossroads Orthopedics, LLC : $36.8K total payments, HHI 238
- Seqirus USA Inc : $339.2K total payments, HHI 236
- Spinal Simplicity, LLC : $752.6K total payments, HHI 235
- Celltrion USA Inc. : $844.6K total payments, HHI 234
- Currax Pharmaceuticals LLC : $232.2K total payments, HHI 233
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Endo Pharmaceuticals Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Endo Pharmaceuticals Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Endo Pharmaceuticals Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Cala Health, Inc.
$602.0K 123 recipients
Compare payment profiles
Arena Pharmaceuticals, Inc.
$606.7K 6 recipients
Compare payment profiles
OrthoFundamentals, LLC
$607.3K 15 recipients
Compare payment profiles
Bone Support Inc.
$613.3K 1,376 recipients
Compare payment profiles
Aroa Biosurgery Incorporated
$591.0K 3,872 recipients
Compare payment profiles
Put this to use
Endo Pharmaceuticals Inc. ranks #724 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Endo Pharmaceuticals Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.